articleJournal of Lipid ResearchNov 20, 2008HYBRID OA

PCSK9: a convertase that coordinates LDL catabolism

Howard Hughes Medical Institute · Southwestern Medical Center · +1 more institution

PubMed
Indexed incrossrefdoajpubmed

Abstract

The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD). PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for degradation. Individuals with loss-of-function mutations in PCSK9 have reduced plasma levels of LDL cholesterol and are protected from CHD; these observations have validated PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention of CHD. The identification and characterization of proprotein convertase…

No related works found for this paper.